Key facts
- It has raised $2.1M; the latest was Early Stage VC ($2.1M) in Nov 2024.
- Notable investors include Innovatiefonds Noord-Holland, ROM Utrecht Region, AMC Ventures Holding, BioGeneration Ventures, Utrecht Health Seed Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Phlox Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Phlox Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phlox Therapeutics
Developer of gene therapeutics intended to alleviate and cure different heart diseases. The company's technology includes gene therapy, an RNA-based therapeutic product and other cardiac therapeutics providing lifelong benefits, enabling patients to reduce the negative effects caused by genetic mutations and to access therapeutic technology that can cure genetic heart diseases.
- Sector
- Healthcare
- HQ
- Naarden, Netherlands
- Founded
- 2022
- Employees
- 7
- Website
- phloxtherapeutics.com/
- Ownership
- Privately Held (backing)
Phlox Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phlox Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phlox Therapeutics in its N-PORT filings yet. We sweep new filings monthly.